How AstraZeneca's revivified pipeline could boost Pfizer
This article was originally published in Scrip
Executive Summary
While the main motive for Pfizer's pursuit of AstraZeneca has been squarely placed at the tax man's door, if the acquisition does go through the US company will find itself in possession of a revivified, but still largely immature, drug pipeline.